Dynavax Technologies

399 articles with Dynavax Technologies

• Medigen's COVID-19 Vaccine Combined with Dynavax's CpG 1018 Adjuvant Receives Taiwan Government Subsidy with First Participant Dosed in Early October

  10/13/2020

  Medigen Vaccine Biologics Corporation and Dynavax Technologies Corporation announced that MVC has obtained a Taiwan government subsidy for successfully initiating a Phase 1 clinical trial in Taiwan.

• TriSalus Life Sciences Lays Out Therapeutic Strategy Upon Acquisition of First Therapeutic Candidate

  9/24/2020

  Initiating clinical trials to evaluate investigational toll-like receptor 9 agonist, SD-101, in patients with uveal melanoma liver metastases followed by three additional indications.

• Dynavax Announces Appointment of New Board Member and Planned Retirement of Chief Financial Officer

  9/24/2020

  - Peter Paradiso, Ph.D., is a senior biopharmaceutical executive with over three decades of experience in the vaccine industry - Michael Ostrach, Senior Vice President, Chief Financial Officer and Chief Business Officer, has communicated his planned retirement in 2021

• Valneva and Dynavax Announce Commercial Supply Agreement for Inactivated, Adjuvanted COVID-19 Vaccine

  9/14/2020

  Dynavax will provide CpG 1018 to produce up to 190 million doses over a five year period to support Valneva's contract with the U.K. government

• Dynavax Announces Grant to Scale up CpG 1018 Adjuvant Capacity to Support the Global COVID-19 Response

  8/13/2020

  Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced a grant from the Bill & Melinda Gates Foundation of $3.4 million to scale up production batch size to allow for increased capacity of Dynavax’s CpG 1018 advanced adjuvant to support the global COVID-19 response. These efforts will support capacity of up to 750 million adjuvant d

• Dynavax Announces Second Quarter 2020 Financial Results

  8/6/2020

  Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing novel vaccines, reported financial results for the second quarter of 2020.

• TriSalus Life Sciences Acquires Dynavax’s SD-101 Oncology Program in Purchase Agreement for up to $250 million in Milestone Payments plus Royalties on Future Net Sales

  8/3/2020

  SD-101 is a proprietary investigational, second-generation, Toll-like receptor 9 (TLR9) agonist CpG-C class oligodeoxynucleotide

• Dynavax to Report Second Quarter 2020 Financial Results and Host Conference Call on August 6, 2020

  7/30/2020

  Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report second quarter 2020 financial results on Thursday, August 6, 2020, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Thursday, August 6, 2020 at 4:30 p.m. (ET)/1:30 p.m. (PT). The live audio webcast may be accessed through the “Events &am

• Dynavax and Medigen Announce Collaboration to Develop a Novel Adjuvanted COVID-19 Vaccine Candidate

  7/23/2020

  Collaboration focused on developing an adjuvanted COVID-19 vaccine using Medigen’s subunit vaccine candidate with Dynavax’s CpG 1018 In preclinical testing, the combination generated strong virus neutralizing antibody responses Medigen anticipates initiating a Phase 1 clinical trial evaluating the combination in September 2020

• Dynavax and Mount Sinai Announce Collaboration to Develop a Universal Influenza Vaccine Candidate with CpG 1018 Adjuvant

  7/16/2020

  Development funded under contract award from NIAID/NIH as part of the CIVICs program Currently no approved universal influenza vaccine CDC estimates 35.5 million people were infected with influenza in U.S. during 2018-2019 season Collaboration will combine Dynavax’s CpG 1018 with influenza antigens designed to protect against all strains of influenza NEW YORK and EMERYVILLE, Calif., July 16, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical c

• Dynavax Announces First Participants Dosed in Phase 1 Clinical Trial Evaluating Medicago’s COVID-19 Vaccine Candidate with Dynavax’s CpG 1018 Adjuvant

  7/14/2020

  Medicago expects to enroll 180 healthy adult participants Preliminary safety and immunogenicity results are expected in October 2020 Dynavax is providing CpG 1018, the adjuvant contained in its U.S. FDA-approved adult hepatitis B vaccine, to enhance the immune response of Medicago’s COVID-19 vaccine candidate

• Dynavax to Present at the H.C. Wainwright Virtual Fireside Chat Series

  6/22/2020

  Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer , Chief Executive Officer, will participate in a virtual fireside chat at the H.C. Wainwright Virtual Fireside Chat Series on Thursday, June 25, at 10:50 a.m. E.T. The presentation will be webcast and may be accessed through the “Events & Presentations” page on

• Dynavax Announces First Participants Dosed in Phase 1 Clinical Trial Evaluating Clover Biopharmaceuticals’ COVID-19 S-Trimer Vaccine Candidate with CpG 1018 Adjuvant

  6/19/2020

  Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing novel vaccines, announced that the first participants have been dosed in the Phase 1 clinical trial to evaluate Clover Biopharmaceuticals’ vaccine candidate to prevent COVID-19 that contains the Company’s CpG 1018 adjuvant.

• Dynavax Completes Enrollment of Clinical Trial Evaluating HEPLISAV-B in Patients Undergoing Hemodialysis

  6/9/2020

  Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing novel vaccines, announced it has completed enrollment of 119 patients in the clinical trial evaluating HEPLISAV-B® [Hepatitis B Vaccine, Adjuvanted] in adults with end-stage renal disease who are initiating or undergoing hemodialysis.

• Dynavax to Present at the William Blair 40th Annual Growth Stock Conference

  5/28/2020

  Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer, Chief Executive Officer, will participate in a virtual fireside chat at the William Blair 40th Annual Growth Stock Conference on Tuesday, June 9, at 12:00 p.m. C.T.

• Dynavax Technologies Announces Closing of $80.5 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

  5/27/2020

  Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the closing of its previously announced underwritten public offering of 16,100,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 2,100,000 shares,

• 

  Biotech Bay Companies Fighting Against COVID-19

  5/26/2020

  Biotech Bay, the bustling biotech industry around San Francisco in California, is home to many biopharma companies developing diagnostics, therapies, and vaccines to fight against coronavirus disease 2019 (COVID-19) and the virus that causes it, called SARS-CoV-2.

• Dynavax Technologies Announces Proposed Public Offering of Common Stock - May 21, 2020

  5/21/2020

  Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing novel vaccines, announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.

• Dynavax Announces First Quarter 2020 Financial Results

  5/7/2020

  Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing novel vaccines, reported financial results for the first quarter of 2020.

• Dynavax Reports Interim Analysis of Ongoing Clinical Trial Evaluating HEPLISAV-B in Patients Undergoing Hemodialysis

  4/28/2020

  Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing novel vaccines, reported immunogenicity and safety data from an interim analysis of the ongoing clinical trial evaluating HEPLISAV-B® [Hepatitis B Vaccine, Adjuvanted] in patients undergoing hemodialysis.